Talphera TLPH
NASDAQ TLPH
$1.24 +0.01 (+1.23%)
As of: Sep 10, 2026 · 1:39 PM EDT

Talphera (TLPH) Non Operating Interest Expenses (2010 - 2023)

Talphera (TLPH) posted Non Operating Interest Expenses of $15000.0 for Q2 2023, down 92.02% on a QoQ basis from $188000.0 in Q4 2022, and down 94.88% year-over-year from $293000.0 in Q2 2022.

Analysis

Talphera (TLPH) Non Operating Interest Expenses (2010 - 2023) Analysis & Trends

Talphera has reported Non Operating Interest Expenses for 14 years, with the latest figure at $15000.0 in Q2 2023.

  • On a quarterly basis, Non Operating Interest Expenses fell 94.88% year-over-year to $15000.0 in Q2 2023; TTM through Jun 2024 was $15000.0, a 97.98% decrease from a year earlier, with the FY2023 full-year figure at $134000.0, down 87.99% from the prior year.
  • Non Operating Interest Expenses was $15000.0 for Q2 2023 at Talphera, down from $188000.0 in the prior quarter.
  • The five-year high for Non Operating Interest Expenses was $872000.0 in Q2 2020, with the low at $15000.0 in Q2 2023.
  • Average Non Operating Interest Expenses over 5 years is $544823.5, with a median of $538000.0 recorded in 2021.
  • The sharpest annual moves came in 2020 and 2023: Non Operating Interest Expenses soared 127.39% in 2020, then plunged 94.88% in 2023.
  • Over 5 years, Non Operating Interest Expenses stood at $831000.0 in 2019, then fell by 9.27% to $754000.0 in 2020, then plunged by 38.06% to $467000.0 in 2021, then sank by 59.74% to $188000.0 in 2022, then slumped by 92.02% to $15000.0 in 2023.
  • The last three Non Operating Interest Expenses figures came in at $15000.0 (Q2 2023), $188000.0 (Q4 2022), and $245000.0 (Q3 2022), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Amgen 206.67 Bn 192.69 Bn 7.24 Bn 673.00 Mn
2 Gilead Sciences 180.06 Bn 176.88 Bn 6.22 Bn 247.00 Mn
3 Vertex Pharmaceuticals 131.44 Bn 123.59 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 81.94 Bn 73.95 Bn 3.93 Bn 11.00 Mn
5 Argenx Se 60.28 Bn 55.10 Bn 1.37 Bn -1.00 Mn
6 Moderna 53.87 Bn 48.73 Bn 52.00 Mn -
7 Alnylam Pharmaceuticals 33.15 Bn 29.85 Bn 992.69 Mn 82.05 Mn
8 Biogen 31.88 Bn 30.60 Bn 1.96 Bn -
9 Roivant Sciences 29.16 Bn 29.16 Bn 1.16 Mn -
10 Talphera 93.28 Mn 93.28 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2023 15,000.00
Dec 31, 2022 188,000.00
Sep 30, 2022 245,000.00
Jun 30, 2022 293,000.00
Mar 31, 2022 390,000.00
Dec 31, 2021 467,000.00
Sep 30, 2021 538,000.00
Jun 30, 2021 614,000.00
Mar 31, 2021 672,000.00
Dec 31, 2020 754,000.00
Sep 30, 2020 824,000.00
Jun 30, 2020 872,000.00
Mar 31, 2020 855,000.00
Dec 31, 2019 831,000.00
Sep 30, 2019 828,000.00
Jun 30, 2019 500,000.00
Mar 31, 2019 376,000.00
Dec 31, 2018 459,000.00
Sep 30, 2018 529,000.00
Jun 30, 2018 586,000.00